Wegovy

Page 5 of 6

Lars Fruergaard Jorgensen, chief executive officer Novo Nordisk
Retail

Denmark’s Novo Nordisk forecasts 27% sales surge but faces price pressure amid Eli Lilly competition

By Naomi Kresge and Bloomberg
May 2, 2024
Novo Nordisk CEO Lars Fruergaard Jorgensen Interview
Retail

Novo Nordisk’s market value of $570 billion is now bigger than the entire Danish economy—creating a ‘Nokia risk’ for Denmark

By Sanne Wass, Naomi Kresge and Bloomberg
May 1, 2024
Lars Fruergaard Jorgensen
Health

No evidence Ozempic and Wegovy raise risk of self harm, EU regulators said

By Jonel Aleccia and The Associated Press
April 13, 2024
Study shows Wegovy eases heart-failure symptoms for patients with diabetes—helpful to Novo as it argues insurers should pay for it
Health

Study shows Wegovy eases heart-failure symptoms for patients with diabetes—helpful to Novo as it argues insurers should pay for it

By Naomi Kresge and Bloomberg
April 6, 2024
Ozempic maker Novo Nordisk facing pressure as study finds $1,000 appetite suppressant can be made for just $5
Health

Ozempic maker Novo Nordisk facing pressure as study finds $1,000 appetite suppressant can be made for just $5

By Madison Muller, Robert Langreth and Bloomberg
March 28, 2024
A person using Ozempic
Retail

Wegovy and Ozempic have ignited a gold rush in pharma as well as an upsurge in fake ‘skinny jabs’, leading to surge in hospitalizations

By Ashleigh Furlong and Bloomberg
March 13, 2024
tube of wegovy injections
Lifestyle

Novo Nordisk eclipses Tesla on positive trial results for a weight loss drug that may be more powerful than its own Wegovy 

By
March 8, 2024
62-year-old who lost 40 pounds in 9 months on Wegovy wants to stop the treadmill: ‘At some point you have to come off of them. I don’t want to be on them forever’
Health

62-year-old who lost 40 pounds in 9 months on Wegovy wants to stop the treadmill: ‘At some point you have to come off of them. I don’t want to be on them forever’

By Jonel Aleccia and The Associated Press
March 7, 2024
Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity.
Retail

Novo Nordisk’s Wegovy and Ozempic boom saved Denmark’s GDP from a no-growth 2023—and will help double its expected growth this year, country’s largest bank says

By Niclas Rolander and Bloomberg
March 5, 2024
Novo Nordisk’s CEO says he’s fielding calls from ‘scared’ junk food suppliers asking for advice over Ozempic surge
Retail

Novo Nordisk’s CEO says he’s fielding calls from ‘scared’ junk food suppliers asking for advice over Ozempic surge

By
February 8, 2024
Lars Fruergaard Jorgensen holding flashcards and talking
Retail

Novo Nordisk CEO says he was ‘surprised’ to see the popularity of weight-loss drugs in Europe—and people’s readiness to pay out of pocket for them

By
February 5, 2024
Novo Nordisk hits $500B market value, climbing closer to the $1T club as it forecasts Wegovy and Ozempic will juice another 29% jump in profits this year
Retail

Novo Nordisk hits $500B market value, climbing closer to the $1T club as it forecasts Wegovy and Ozempic will juice another 29% jump in profits this year

By
January 31, 2024
North Carolina drops coverage for Wegovy and Ozempic, with implications for anti-obesity drug market projected to hit $100B by 2030
Health

North Carolina drops coverage for Wegovy and Ozempic, with implications for anti-obesity drug market projected to hit $100B by 2030

By Simone Foxman, Madison Muller and Bloomberg
January 27, 2024
Ozempic, Wegovy demand so strong Europe’s most valuable listed company plans ‘mega manufacturing facility’
Health

Ozempic, Wegovy demand so strong Europe’s most valuable listed company plans ‘mega manufacturing facility’

By Ellie Harmsworth and Bloomberg
December 24, 2023
Ozempic manufactured by Novo Nordisk packaging on December 7, 2023.
Health

Novo Nordisk became Europe’s most valuable company with the rise of Wegovy and Ozempic, but it’s facing stiff competition from a local pharma rival

By Christian Wienberg and Bloomberg
December 13, 2023

Most Popular